Details for Patent: 9,687,474

Which drugs does patent 9,687,474 protect, and when does it expire?

Patent 9,687,474 protects SECUADO and is included in one NDA.

This patent has thirty-eight patent family members in nine countries.

Summary for Patent: 9,687,474

Title:	Patch
Abstract:	In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent.
Inventor(s):	Masayuki Suzuki, Hiroaki Okutsu, Takashi Yasukochi, Yasunori Takada
Assignee:	Hisamitsu Pharmaceutical Co Inc
Application Number:	US14/416,964
Patent Claim Types: see list of patent claims	Compound;

US Patent 9,687,474: Asenapine Transdermal Patch Claims, Exclusivity, and Patent Landscape

US Patent 9,687,474 protects a transdermal asenapine patch that combines an asenapine active ingredient, isopropyl palmitate, sodium diacetate, and an adhesive base. Its commercially relevant protection is directed to the formulation architecture and specified pharmacokinetic performance, rather than to asenapine as a chemical compound.

The patent was assigned to Hisamitsu Pharmaceutical Co., Inc. and is associated with the Secuado brand, an asenapine transdermal system marketed by Noven Pharmaceuticals. The patent issued on June 27, 2017, from a U.S. national-stage application and has an estimated expiration date in 2033, subject to the official patent-term calculation and any applicable adjustments [1].

What does US Patent 9,687,474 protect?

The patent protects a multilayer transdermal patch comprising:

1. A support layer.
2. An adhesive agent layer formed on the support layer.
3. Asenapine or a pharmaceutically acceptable salt, typically asenapine maleate.
4. Isopropyl palmitate.
5. Sodium diacetate.
6. A defined ratio between asenapine and isopropyl palmitate.

The independent claim requires a mass ratio of free asenapine to isopropyl palmitate between 1:0.1 and 1:5. The claim also requires sodium diacetate, although claim 1 does not impose a numerical asenapine-to-sodium-diacetate ratio. Dependent claim 3 narrows that relationship to a molar ratio of 1:0.5 to 1:4.

The patent therefore covers a specific adhesive-matrix formulation, not every asenapine patch.

Core claim limitations

Limitation	Required by claim 1?	Commercial significance
Support layer	Yes	Standard patch structural element
Adhesive agent layer	Yes	Drug-in-adhesive delivery system
Asenapine or pharmaceutically acceptable salt	Yes	Active pharmaceutical ingredient
Isopropyl palmitate	Yes	Permeation-enhancing or formulation component
Adhesive base agent	Yes	Controls adhesion and drug release
Sodium diacetate	Yes	Formulation component included in the claimed combination
Free-asenapine:isopropyl-palmitate mass ratio of 1:0.1 to 1:5	Yes	Principal quantitative limitation
Free-asenapine:isopropyl-palmitate ratio of 1:0.41 to 1:5	No, claim 2 only	Narrower quantitative subrange
Asenapine:sodium-diacetate molar ratio of 1:0.5 to 1:4	No, claim 3 only	Additional formulation restriction
Defined AUC and metabolite exposure	No, claim 5 and related claims	Pharmacokinetic limitation

How broad are the independent and dependent claims?

Claim 1 is the principal composition claim. It is relatively broad within the claimed formulation concept because it does not restrict the adhesive base to a single polymer or require the pharmacokinetic result in the claim language.

Claims 2 through 17 narrow claim 1 through combinations of:

• A narrower isopropyl-palmitate range.
• A sodium-diacetate molar ratio.
• Specified classes of adhesive polymers.
• A pharmacokinetic profile based on a 3.4 mg free-asenapine loading.

The claim set uses multiple dependency paths. This creates fallback positions if a court or patent office rejects the broader formulation claim.

Adhesive-base coverage

Claims 4, 7, 9, and 13 cover adhesive bases selected from:

• (Meth)acrylic ester polymers or copolymers.
• Rubber-based adhesives.
• Silicone polymers.
• Polyurethane-based adhesives.

These claims are broad at the category level. They do not, on their face, require a particular commercial adhesive grade, polymer molecular weight, crosslinking system, or tackifier. A competing product using one of these adhesive classes may still avoid infringement if it omits another required element or falls outside the claimed ratio ranges.

Pharmacokinetic coverage

Claim 5 and the claims depending from it require that, for a patch containing 3.4 mg of free asenapine:

• The AUC2-120 for free asenapine is at least 27,000 pg·hr/mL.
• The AUC2-120 of an asenapine metabolite is no more than 20% of the free-asenapine AUC2-120.

The term AUC2-120 refers to the area under the plasma concentration-time curve from two hours through 120 hours after skin contact. The claim language links formulation composition with an in vivo exposure result. This can complicate infringement analysis because composition alone may not establish infringement of the pharmacokinetic claims. Testing may be required to determine whether the accused patch meets the claimed exposure profile.

What patent numbers protect Secuado and transdermal asenapine?

US Patent 9,687,474 is one of the principal U.S. formulation patents associated with Secuado. The relevant protection should be analyzed as a patent family rather than as an isolated grant.

Patent-family and product relationship

Item	Information
Product	Secuado
Active ingredient	Asenapine transdermal system
Developer and marketing company	Noven Pharmaceuticals
Originator technology owner associated with patent	Hisamitsu Pharmaceutical Co., Inc.
U.S. patent	9,687,474
Patent title	Patch
Issue date	June 27, 2017
FDA approval	October 11, 2019
Dosage form	Transdermal system
Orange Book pathway	NDA-listed drug product
Estimated patent expiry	2033, based on the applicable U.S. patent term

The FDA approved Secuado under NDA 214985 for the treatment of adults with schizophrenia [2]. The product is a small-molecule drug-device combination in which the drug is incorporated into an adhesive transdermal system.

A complete freedom-to-operate review should include continuation, divisional, foreign counterpart, and later-issued U.S. family patents. The existence of related family patents can preserve protection even if one claim set is narrowed or invalidated.

When does US Patent 9,687,474 expire?

The patent is expected to expire in 2033. The relevant baseline is the 20-year term measured from the applicable earliest U.S. or international nonprovisional filing date, rather than from the issue date [3].

The patent therefore does not expire 20 years after its 2017 grant. Its issue date is relevant to enforceability and prosecution history, but the term is principally controlled by the earlier application filing dates.

Exclusivity timeline for Secuado

Event	Date or period
U.S. patent grant	June 27, 2017
FDA approval of Secuado	October 11, 2019
Five-year NCE exclusivity	Generally through October 11, 2024
Earliest ordinary ANDA filing point	Approximately October 11, 2023, assuming the NCE-1 framework applied
Estimated patent expiry	2033
Practical generic-entry exposure	Potentially after patent expiry, unless a successful Paragraph IV challenge or settlement permits earlier entry

Asenapine itself is an old active ingredient. The commercial barrier for Secuado is therefore the transdermal formulation and related product-specific rights, not new chemical entity protection for asenapine.

What is the Orange Book status of US Patent 9,687,474?

Secuado is an FDA-approved NDA product, and its product-specific patents are evaluated through the FDA Orange Book listing process. Orange Book listing is important because it gives an ANDA applicant notice of patents that the NDA holder identifies as claiming the drug, formulation, or approved method of use [4].

For an ANDA applicant, a listed patent can require one of four certifications:

• Paragraph I: no patent information has been submitted.
• Paragraph II: the patent has expired.
• Paragraph III: the applicant will wait until patent expiration.
• Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

The commercial importance of US 9,687,474 depends on whether it remains listed for the relevant Secuado strengths and whether any later patent or regulatory exclusivity remains effective. Orange Book listings should be checked by NDA, product strength, and current patent status because listing information can change through delisting, expiration, corrections, or new patent submissions.

What Paragraph IV challenges could affect Secuado?

A generic applicant seeking approval before the 2033 patent expiry would likely need to address US 9,687,474 through a Paragraph IV certification if the patent remains listed and the applicant seeks an early launch.

A Paragraph IV strategy could target:

1. Anticipation or obviousness of the claimed combination.
2. Written-description support for the full ratio ranges.
3. Enablement across the entire adhesive-base and ratio scope.
4. Indefiniteness of terms such as “adhesive base agent.”
5. Inherency of the claimed AUC profile.
6. Failure of an accused product to meet the numerical ratio or pharmacokinetic limitations.

The patent’s strongest litigation position is likely claim 1, because it does not require the AUC limitations. A generic applicant that uses asenapine, sodium diacetate, isopropyl palmitate, and an adhesive base within the claimed ratio range could face a direct formulation-infringement theory.

The narrower claims provide additional enforcement positions but also introduce more measurable limitations. A challenger may avoid claims 2, 3, or 5 by adjusting the enhancer ratio, sodium-diacetate ratio, asenapine loading, or resulting exposure profile.

What generic entry risks exist for Secuado?

The likely generic-entry scenarios are:

Scenario 1: Launch after patent expiry

This is the lowest litigation-risk pathway. An ANDA applicant can certify Paragraph III for the listed patent and target approval after the relevant 2033 expiration date. The timing may still depend on other listed patents, pediatric exclusivity, regulatory review, and FDA requirements for demonstrating transdermal equivalence.

Scenario 2: Paragraph IV challenge

A challenger may assert that its patch does not infringe or that the patent is invalid. A successful Paragraph IV challenge could enable entry before 2033. The risk is highest if the proposed product closely follows the Secuado formulation architecture.

Scenario 3: Design-around patch

A competitor could seek to omit or replace one required claim element. Potential design-around variables include:

• Replacing isopropyl palmitate with another permeation enhancer.
• Omitting sodium diacetate.
• Using a different adhesive matrix.
• Moving the active ingredient into a reservoir or separate drug layer.
• Selecting ratios outside the claimed ranges.
• Developing a different dose and exposure profile.

A design-around must be evaluated against every claim limitation, including equivalents. Avoiding one dependent claim does not avoid claim 1.

Scenario 4: Authorized generic or license-backed entry

A settlement, license, or authorized-generic arrangement could permit earlier entry while preserving part of the originator’s commercial position. Publicly available patent information alone does not establish the existence or terms of a private license.

How strong is the patent estate for transdermal asenapine?

The estate has meaningful formulation strength because claim 1 combines structural, compositional, and quantitative limitations. The patent does not depend on a narrow brand name or a single adhesive polymer. It reaches several adhesive-base categories and a relatively wide isopropyl-palmitate ratio.

Its principal vulnerabilities are technical and claim-construction related:

Issue	Impact
Known asenapine active ingredient	Weakens any argument based on novelty of the molecule
Combination of sodium diacetate and isopropyl palmitate	Supports combination novelty and nonobviousness arguments
Broad adhesive-base categories	Increases coverage but may invite prior-art and enablement attacks
Numerical ratio ranges	Creates objective infringement tests but enables formulation design-arounds
AUC limitations	Can support unexpected-results arguments but may require extensive testing
Patch architecture	Provides a direct product claim against closely matching systems
2033 term	Creates a long post-approval formulation barrier

The patent’s commercial value is highest against a generic that copies the drug-in-adhesive design. Its value is lower against a product using a different enhancer system, different salt-handling approach, or a different delivery architecture.

What formulations are protected by US 9,687,474?

The protected formulation must include all elements of an asserted claim. At minimum under claim 1, the patch must contain:

• Asenapine or an acceptable salt.
• Isopropyl palmitate.
• Sodium diacetate.
• An adhesive base agent.
• A support layer.
• The claimed free-asenapine-to-isopropyl-palmitate ratio.

The patent reaches formulations using acrylic, rubber, silicone, or polyurethane adhesive systems under the dependent claims. The 3.4 mg limitation applies to the pharmacokinetic claims, not necessarily to the basic composition claim.

Likely non-infringing formulation directions

A competing developer could investigate:

• A patch without sodium diacetate.
• A patch without isopropyl palmitate.
• A formulation using a different enhancer.
• A matrix with a ratio below 0.1 or above 5 parts isopropyl palmitate per part free asenapine.
• A nonadhesive reservoir system.
• A delivery system using a different active form or formulation environment.

Each route creates development, adhesion, skin-permeation, stability, and bioequivalence risks. A theoretical design-around is not a regulatory substitute for demonstrating equivalent delivery and tolerability.

What FDA regulatory issues affect generic transdermal asenapine?

A generic Secuado applicant would likely pursue an ANDA if FDA determines that the transdermal system can be approved as therapeutically equivalent through the abbreviated pathway. The applicant would need to address:

• Same active ingredient.
• Same dosage form and route.
• Strength and dose delivery.
• Adhesion performance.
• Drug release and permeation.
• Product quality and manufacturing controls.
• Bioequivalence or comparative pharmacokinetic requirements.
• Device constituent performance, where applicable.

Transdermal products can present greater regulatory complexity than conventional oral generics because adhesion, wear time, drug release, skin permeation, and residual drug can affect clinical performance.

Asenapine sublingual products such as Saphris are not direct substitutes for Secuado in an ANDA analysis. They use a different dosage form, route, release profile, and administration method. They also do not remove the formulation-patent risk associated with a copied asenapine patch.

What patent litigation and settlement risks affect Secuado?

A Paragraph IV notice would create potential litigation under the Hatch-Waxman framework. If the NDA holder sued within the statutory period, FDA approval could be subject to a 30-month stay, subject to statutory exceptions and court developments [5].

The central litigation questions would likely be:

• Whether the proposed patch contains sodium diacetate.
• Whether the free-asenapine-to-isopropyl-palmitate ratio falls within the claimed range.
• Whether the adhesive base qualifies under the patent.
• Whether pharmacokinetic claims are met.
• Whether the patent is obvious in view of prior transdermal asenapine and permeation-enhancer references.
• Whether the asserted claims are enabled across their full scope.

No conclusion about an active settlement or a specific Paragraph IV case follows from the patent claims alone. The operative risk assessment requires the current Orange Book record and federal court docket history.

How does US 9,687,474 compare with the original asenapine patents?

Protection category	US 9,687,474	Original asenapine patents
Protected subject matter	Transdermal patch formulation	Asenapine compound and earlier pharmaceutical uses
Product relevance	Secuado	Saphris and other asenapine products
Main barrier	Formulation copying	Historical compound and use rights
Expected term position	Extends into 2033	Generally expired or substantially earlier
Generic strategy	Formulation design-around or Paragraph IV	Conventional generic asenapine pathways
Biosimilar relevance	None	None

Asenapine is a small molecule, so biosimilar legislation does not apply. Competitive entry would proceed through generic-drug mechanisms, not a biologics license application or biosimilar application.

Key Takeaways

• US Patent 9,687,474 protects a specific asenapine drug-in-adhesive transdermal patch.
• Claim 1 requires isopropyl palmitate, sodium diacetate, an adhesive base, and a defined free-asenapine-to-isopropyl-palmitate mass ratio.
• Dependent claims add sodium-diacetate ratios, adhesive categories, and AUC-based pharmacokinetic requirements.
• The patent is associated with Secuado and is expected to remain relevant through approximately 2033.
• The principal generic risk is a closely copied patch using the same excipients and ratio ranges.
• A successful design-around may omit sodium diacetate or isopropyl palmitate, change the adhesive architecture, or move outside the claimed ratios.
• Secuado is a small-molecule transdermal product. Biosimilar risk does not apply.
• A Paragraph IV challenger would face both patent-validity issues and the technical burden of demonstrating transdermal equivalence.
• The strongest commercial protection is the broad composition claim. The pharmacokinetic claims provide narrower but potentially valuable fallback protection.

FAQs

Can a patch infringe US 9,687,474 if it uses asenapine free base instead of asenapine maleate?

Yes. The claims expressly cover asenapine and pharmaceutically acceptable salts, with ratios calculated in terms of free asenapine. A free-base product could infringe if it satisfies the other limitations.

Does claim 1 require the patch to contain 3.4 mg of asenapine?

No. The 3.4 mg limitation appears in claim 5 and related dependent claims. Claim 1 does not impose that specific asenapine content.

Can changing the adhesive polymer avoid infringement?

Not necessarily. Claims 4, 7, 9, and 13 cover multiple adhesive classes. Changing from an acrylic adhesive to a rubber, silicone, or polyurethane adhesive may remain within dependent-claim scope if the other elements are present.

Are Saphris and Secuado covered by the same patent rights?

No. Saphris is a sublingual asenapine product, while Secuado is a transdermal system. US 9,687,474 is directed to the transdermal formulation and does not generally cover ordinary sublingual asenapine products.

What is the most effective technical design-around?

The most direct design-around opportunities are omission or replacement of sodium diacetate or isopropyl palmitate, use of a different delivery architecture, or selection of a formulation ratio outside the claimed range. Regulatory performance and other patent-family claims remain separate constraints.

References

1. United States Patent and Trademark Office. (2017). US Patent No. 9,687,474, Patch. U.S. Department of Commerce.
2. U.S. Food and Drug Administration. (2019). Secuado approval letter and prescribing information, NDA 214985.
3. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources. U.S. Department of Commerce.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

Drugs Protected by US Patent 9,687,474

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-001	Oct 11, 2019		RX	Yes	Yes			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-002	Oct 11, 2019		RX	Yes	No			Y
Hisamitsu	SECUADO	asenapine	SYSTEM;TRANSDERMAL	212268-003	Oct 11, 2019		RX	Yes	No			Y

Foreign Priority and PCT Information for Patent: 9,687,474

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2012-165793	Jul 26, 2012
Japan	2013-078583	Apr 4, 2013

PCT Information
PCT Filed	July 25, 2013	PCT Application Number:	PCT/JP2013/070196
PCT Publication Date:	January 30, 2014	PCT Publication Number:	WO2014/017594

International Family Members for US Patent 9,687,474

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	104487071
China	104487072
China	104507472
European Patent Office	2878298